Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in MDD with Early Dementia
NCT04294654Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Feb 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Change in Montgomery and Åsberg Depression Rating Scale Total Score at 12 weeks. Started Feb 2020; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04294654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294654.